Olema Pharmaceuticals Inc
$ 16.30
2.32%
14 Apr - close price
- Market Cap 1,388,410,000 USD
- Current Price $ 16.30
- High / Low $ 16.51 / 15.83
- Stock P/E N/A
- Book Value 5.88
- EPS -1.85
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.37 %
- 52 Week High 36.26
- 52 Week Low 3.89
About
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.
Analyst Target Price
$43.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-10 | 2025-08-11 | 2025-05-06 | 2025-03-10 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-03-11 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.5044 | -0.49 | -0.51 | -0.36 | -0.51 | -0.6 | -0.54 | -0.56 | -0.49 | -0.48 | -0.49 | -0.7 |
| Estimated EPS | -0.5215 | -0.4702 | -0.38 | -0.55 | 0.1732 | -0.58 | -0.55 | -0.55 | -0.48 | -0.51 | -0.73 | -0.66 |
| Surprise | 0.0171 | -0.0198 | -0.13 | 0.19 | -0.6832 | -0.02 | 0.01 | -0.01 | -0.01 | 0.03 | 0.24 | -0.04 |
| Surprise Percentage | 3.279% | -4.211% | -34.2105% | 34.5455% | -394.4573% | -3.4483% | 1.8182% | -1.8182% | -2.0833% | 5.8824% | 32.8767% | -6.0606% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.52 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OLMA
2026-04-11 06:08:56
Wall Street Zen upgraded Olema Pharmaceuticals (OLMA) from a "strong sell" to a "sell" rating. Despite this, the consensus rating from analysts remains a "Moderate Buy" with a target price of $44.40. Insiders have recently sold shares totaling approximately $5.97 million, while institutional investors hold a significant 91.78% stake in the company.
2026-04-10 20:40:25
Olema Pharmaceuticals is creating a new role for an associate director of Good Clinical Practice (GCP) quality assurance to enhance compliance in its clinical studies. This move highlights the company's commitment to high standards as it develops its oncology pipeline, ensuring regulatory alignment and operational excellence. The company also recently posted for a senior director of accounting operations and financial reporting and reported its Q4 and full-year 2025 financial results.
2026-04-06 16:11:11
SG Americas Securities LLC acquired a new stake of 69,382 shares in Olema Pharmaceuticals (NASDAQ:OLMA) during Q4, valued at approximately $1.735 million. This purchase represents about 0.10% ownership, alongside increased stakes from other institutional investors like Goldman Sachs. Olema Pharmaceuticals, with a market cap of $1.31 billion, holds a "Moderate Buy" consensus rating from analysts, targeting an average price of $44.40.
2026-04-06 06:39:48
Olema Pharmaceuticals, Inc. (Olema Oncology) announced the grant of stock options to four new employees, totaling 188,500 shares of common stock. These grants, approved by the Compensation Committee, are an inducement for employment under the company's 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The options vest over four years and have an exercise price of $15.12 per share, based on the April 1, 2026, Nasdaq closing price.
2026-04-03 03:10:29
Olema Pharmaceuticals, Inc. announced that it granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock. These grants, effective April 1, 2026, were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, have a 10-year term, and an exercise price of $15.12 per share.
2026-04-02 16:30:00
Olema Pharmaceuticals, Inc. (Olema Oncology) announced that it granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock. These grants were made under the Company's 2022 Inducement Plan and are in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years with an exercise price of $15.12 per share.
